Prof Robert Coleman speaks to ecancer about the bone health guidelines presented at ESMO 2020 meeting this year.
He first outlined the reasoning for why a guideline change was needed and how he brought about these changes for ESMO 2020.
He further explained how the bone health guidelines have been altered to meet the current needs of the patients.
Prof Coleman wrapped up with highlighting the importance of treating metastatic bone disease with bone targeted agents.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.